Connect with us

BIOTECH

AbbVie Inc (NYSE:ABBV) Records CHMP Positive Feedback For MAVIRET™

Published

on

AbbVie Inc (NYSE:ABBV) reported that the European CHMP of the European Medicines Agency has granted a promising opinion suggesting marketing approval of MAVIRET™, an investigational, pan-genotypic therapy for adults with chronic HCV infection.

If authorized, MAVIRET will be a ribavirin-free, once-daily, 8-week alternative for people without cirrhosis and who are new to therapy across all genotypes, who constitute the majority of people struggling with HCV.1 As per the latest update, the European Commission will assess the CHMP opinion and a final outcome is projected in Q3 2017.

The highlights

Michael Severino, M.D., the Chief Scientific Officer and the EVP of R&D at AbbVie, reported that MAVIRET showcases a new generation of HCV treatment and has the prospect to be an 8-week option for people living with this grave, chronic illness. Today’s CHMP positive stance takes them closer to delivering on company’s objective to address continued unmet needs by getting a new pan-genotypic alternative to people struggling with HCV in Europe.

The CHMP positive opinion is backed by 97.5% SVR12 rates with eight weeks of MAVIRET in GT1-6 chronic HCV infected people minus cirrhosis and who are new to therapy, with diverse patient and viral characteristics. In an integrated assessment, less than 0.4% of people discontinued treatment. The announced adverse reactions were fatigue and headache. The severity and type of adverse reactions in people with cirrhosis were comparable to those noticed in patients without cirrhosis.

While the HCV treatment scope has transformed considerably over recent years, the disease remains to be an international public health problem and treatment concerns remain. Stefan Zeuzem expressed that in clinical trials, MAVIRET showed high SVR rates in different genotypes of HCV patients. If permitted, MAVIRET would eliminate many of the complications of pre-treatment patient assessment and possess the potential to help support the management and care of HCV.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure

BRANDS

DETAILS

SCORE

PRODUCT SITES

  • Certified Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49

9.8

30% OFF Today! “30 0FF”

  • All Natural
  • Made In U.S.A
  • Lab Tested
  • Price From $69

9.7

  • All Natural
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99

9.6

  • All Natural
  • Made In U.S.A
  • Oral Mist
  • Price From $39

9.5

BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49
SCORE

9.8

PRODUCT SITE
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Lab Tested
  • Price From $69
SCORE

9.7

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99
SCORE

9.6

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Oral Mist
  • Price From $39
SCORE

9.5

PRODUCT SITE VIEW PRODUCTS
Advertisement

Title

Uncategorized3 days ago

Top 15 Essential Oils + Health Benefits

Top 15 Essential Oils + Health Benefits Each and every essential oil contains compounds with unique healing and therapeutic benefits....

Uncategorized3 days ago

Using Hemp Oil in Cooking

Hemp oil has many advocates. The oil from hemp seeds is rich in omega-3 and omega-6 essential fatty acids. This makes...

Uncategorized1 week ago

Best Oil Producers of 2018

Millionaires are being made by the moment in the medical marijuana industry. Venture capital firms, private equity firms, and even...

MyDx Inc MyDx Inc
Health3 weeks ago

MyDx Inc. (OTCMKTS:MYDX) Initiates Clinical Trial of Cannabis Formula for The Treatment of Chronic Low Back Pain

San Diego, CA based MyDx Inc. (OTCMKTS:MYDX) has announced the controlled trial of the cannabis formula for the treatment of...

Business3 weeks ago

Fastfunds Financial Corporation (OTCMKTS:FFFC) Is All Set to Launch Affinity Connextions Program Targeting MMJ Industry

Fastfunds Financial Corporation (OTCMKTS:FFFC) has announced the completion of all necessary formalities to introduce an Affinity Connextions Program through a...

Innovative Industrial Properties Inc Innovative Industrial Properties Inc
Business3 weeks ago

Innovative Industrial Properties, Inc (NYSE:IIPR) Unveils Exercise Of Underwriter’s Option To Purchase Common Stock Shares

Innovative Industrial Properties, Inc (NYSE:IIPR) announced recently that it has obtained the exercise of the underwriter’s option to buy additional...

Business3 weeks ago

Next Generation Management Corporation (OTCMKTS:NGMC) Updates On New Medical Marijuana System in Oregon

Nextgen Holdings, a subsidiary of the Next Generation Management Corporation (OTCMKTS:NGMC) recently updated its stockholders with the ongoing Medical Marijuana...

INDUSTRIAL HEMP3 weeks ago

Weed Inc’s (OTCMKTS:BUDZ) Performance Is Getting Higher

Weed Inc (OTCMKTS:BUDZ) has for a long time been enjoying the momentous highs for the past few months. The company’s...

INDUSTRIAL HEMP3 weeks ago

Namaste Technologies Inc (OTCMKTS:NXTTF) Signs A Share Purchase Agreement With Cannbit Ltd

Namaste Technologies Inc (OTCMKTS:NXTTF) announced recently that it signed a non-binding Letter of Intent (LOI) with Cannabit Limited where the...

INDUSTRIAL HEMP3 weeks ago

MariMed Inc. (OTCMKTS:MRMD) Plans To Expand Its Cannabis Business

MeriMed Inc. (OTCMKTS:MRMD) announced its grand plans to expand business into the emerging cannabis industry. Furthermore, the company intends to...

Advertisement
Advertisement
Advertisement